Processa Pharmaceuticals (PCSA) Competitors $0.86 -0.02 (-2.27%) (As of 11/22/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends PCSA vs. ONCT, NKGN, TLPH, AWH, TSBX, PHXM, CDT, INDP, KPRX, and MBIOShould you be buying Processa Pharmaceuticals stock or one of its competitors? The main competitors of Processa Pharmaceuticals include Oncternal Therapeutics (ONCT), NKGen Biotech (NKGN), Talphera (TLPH), Aspira Women's Health (AWH), Turnstone Biologics (TSBX), PHAXIAM Therapeutics (PHXM), Conduit Pharmaceuticals (CDT), Indaptus Therapeutics (INDP), Kiora Pharmaceuticals (KPRX), and Mustang Bio (MBIO). These companies are all part of the "pharmaceutical products" industry. Processa Pharmaceuticals vs. Oncternal Therapeutics NKGen Biotech Talphera Aspira Women's Health Turnstone Biologics PHAXIAM Therapeutics Conduit Pharmaceuticals Indaptus Therapeutics Kiora Pharmaceuticals Mustang Bio Oncternal Therapeutics (NASDAQ:ONCT) and Processa Pharmaceuticals (NASDAQ:PCSA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, risk, earnings, valuation, institutional ownership, community ranking and dividends. Which has more risk and volatility, ONCT or PCSA? Oncternal Therapeutics has a beta of 1.33, indicating that its share price is 33% more volatile than the S&P 500. Comparatively, Processa Pharmaceuticals has a beta of 0.6, indicating that its share price is 40% less volatile than the S&P 500. Does the MarketBeat Community prefer ONCT or PCSA? Oncternal Therapeutics received 18 more outperform votes than Processa Pharmaceuticals when rated by MarketBeat users. However, 58.33% of users gave Processa Pharmaceuticals an outperform vote while only 26.45% of users gave Oncternal Therapeutics an outperform vote. CompanyUnderperformOutperformOncternal TherapeuticsOutperform Votes3226.45% Underperform Votes8973.55% Processa PharmaceuticalsOutperform Votes1458.33% Underperform Votes1041.67% Which has stronger earnings & valuation, ONCT or PCSA? Processa Pharmaceuticals has lower revenue, but higher earnings than Oncternal Therapeutics. Processa Pharmaceuticals is trading at a lower price-to-earnings ratio than Oncternal Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOncternal Therapeutics$790K4.27-$39.48M-$11.69-0.10Processa PharmaceuticalsN/AN/A-$11.12M-$3.39-0.25 Do analysts rate ONCT or PCSA? Oncternal Therapeutics currently has a consensus price target of $20.00, indicating a potential upside of 1,654.39%. Processa Pharmaceuticals has a consensus price target of $6.00, indicating a potential upside of 597.59%. Given Oncternal Therapeutics' higher probable upside, analysts clearly believe Oncternal Therapeutics is more favorable than Processa Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oncternal Therapeutics 0 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.25Processa Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to ONCT or PCSA? In the previous week, Oncternal Therapeutics had 3 more articles in the media than Processa Pharmaceuticals. MarketBeat recorded 4 mentions for Oncternal Therapeutics and 1 mentions for Processa Pharmaceuticals. Oncternal Therapeutics' average media sentiment score of 0.00 equaled Processa Pharmaceuticals'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oncternal Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Processa Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals and insiders hold more shares of ONCT or PCSA? 16.1% of Oncternal Therapeutics shares are held by institutional investors. Comparatively, 91.9% of Processa Pharmaceuticals shares are held by institutional investors. 11.2% of Oncternal Therapeutics shares are held by company insiders. Comparatively, 13.0% of Processa Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Is ONCT or PCSA more profitable? Processa Pharmaceuticals has a net margin of 0.00% compared to Oncternal Therapeutics' net margin of -1,599.95%. Oncternal Therapeutics' return on equity of -177.58% beat Processa Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Oncternal Therapeutics-1,599.95% -177.58% -131.30% Processa Pharmaceuticals N/A -195.21%-163.06% SummaryOncternal Therapeutics and Processa Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks. Ad WealthPressI hate to say I told you soLast month, I openly declared that a Trump Presidency was going to kick off Tesla’s New Bullish Cycle Folks who listened and bought in when I said to are currently crushing it. As a matter of fact, all the trades we’ve opened ever since I made that public declaration have ALL been winners. And it’s simply because this Tesla indicator just flipped green on the stock…Follow this link right away. Get Processa Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PCSA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PCSA vs. The Competition Export to ExcelMetricProcessa PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.88M$6.99B$5.38B$8.84BDividend YieldN/A8.15%5.13%4.09%P/E Ratio-0.2511.10105.1417.83Price / SalesN/A362.031,233.15158.41Price / CashN/A52.5940.4136.29Price / Book0.7510.377.096.50Net Income-$11.12M$153.60M$119.65M$226.22M7 Day Performance-14.83%4.60%2.25%4.03%1 Month Performance-34.84%-6.29%-2.33%4.92%1 Year Performance-90.12%33.41%33.98%29.30% Processa Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PCSAProcessa Pharmaceuticals3.2372 of 5 stars$0.86-2.3%$6.00+597.6%-90.1%$2.88MN/A-0.2520News CoverageONCTOncternal Therapeutics1.9455 of 5 stars$1.12-3.4%$20.00+1,685.7%-82.5%$3.32M$790,000.00-0.1030Analyst ForecastGap DownNKGNNKGen BiotechN/A$0.32-4.2%N/A-87.7%$11.43M$80,000.00-0.07N/ATLPHTalphera2.1949 of 5 stars$0.67-4.2%$4.50+571.6%N/A$11.41M$281,000.00-1.0119Positive NewsGap DownAWHAspira Women's Health1.6508 of 5 stars$0.71-5.1%$4.40+520.0%-76.4%$11.40M$9.15M0.00110Analyst ForecastGap DownTSBXTurnstone Biologics3.206 of 5 stars$0.46-1.3%$2.13+358.6%-80.7%$10.72M$19.31M-0.1482PHXMPHAXIAM TherapeuticsN/A$3.10flatN/AN/A$10.58M$32.66M0.0049CDTConduit PharmaceuticalsN/A$0.11-1.9%N/A-93.9%$10.16MN/A0.003News CoverageINDPIndaptus Therapeutics2.3093 of 5 stars$0.98-5.8%$8.50+763.8%-52.2%$10.04MN/A-0.506KPRXKiora Pharmaceuticals3.0317 of 5 stars$3.28-0.9%$10.00+204.9%-28.4%$9.84MN/A0.0010MBIOMustang Bio1.9589 of 5 stars$0.21-1.3%$2.00+874.7%-86.9%$9.80MN/A-0.13100Gap Down Related Companies and Tools Related Companies Oncternal Therapeutics Alternatives NKGen Biotech Alternatives Talphera Alternatives Aspira Women's Health Alternatives Turnstone Biologics Alternatives PHAXIAM Therapeutics Alternatives Conduit Pharmaceuticals Alternatives Indaptus Therapeutics Alternatives Kiora Pharmaceuticals Alternatives Mustang Bio Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PCSA) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Processa Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Processa Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
